---
title: "CARE reaffirms Godavari Biorefineries’ BBB+ rating amid sector headwinds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279459853.md"
description: "CARE reaffirms Godavari Biorefineries’ BBB+ rating amid sector headwinds"
datetime: "2026-03-17T15:35:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279459853.md)
  - [en](https://longbridge.com/en/news/279459853.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279459853.md)
---

# CARE reaffirms Godavari Biorefineries’ BBB+ rating amid sector headwinds

CARE reaffirms Godavari Biorefineries’ BBB+ rating amid sector headwinds

### Related Stocks

- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [CDMO.US](https://longbridge.com/en/quote/CDMO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [GRI.US](https://longbridge.com/en/quote/GRI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BHVN.US](https://longbridge.com/en/quote/BHVN.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)